Metastatic Poorly Differentiated Prostatic Carcinoma With Neuroendocrine Differentiation Negative on 68Ga-PSMA PET/CT

被引：72

作者：

Chakraborty, Partha Sarathi ^{[1
]}

Tripathi, Madhavi ^{[1
]}

Agarwal, Krishan Kant ^{[1
]}

Kumar, Rajeev ^{[1
]}

Vijay, Maneesh Kumar ^{[2
]}

Bal, Chandrasekhar ^{[1
]}

机构：

[1] All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India

[2] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India

来源：

CLINICAL NUCLEAR MEDICINE | 2015年 / 40卷 / 02期

关键词：

prostate cancer; skeletal scintigraphy; Ga-68-PSMA; PET/CT;

D O I：

10.1097/RLU.0000000000000594

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68(HBED-CC)], abbreviated as Ga-68-PSMA, is a novel radiotracer undergoing evaluation for PET/CT imaging of prostate carcinoma. Its major advantage is the sensitive detection of lesions even at low prostate-specific antigen level and high target-to-background ratios obtained in metastatic lesions, which is better than that obtained with F-18-fluoromethylcholine. We present the case of a 28-year-old man with poorly differentiated prostate carcinoma with neuroendocrine differentiation, whose lesions did not show significant Ga-68-PSMA localization. As literature on utility of Ga-68-PSMA PET/CT for imaging prostate carcinoma grows, it is important to be aware of potential false negatives that could influence study results.

引用

页码：E163 / E166

页数：4

共 8 条

[1] THE COURSE OF NEURO-ENDOCRINE DIFFERENTIATION IN PROSTATIC CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY TESTING CHROMOGRANIN-A AS AN ENDOCRINE MARKER [J].

ABRAHAMSSON, PA ;

FALKMER, S ;

FALT, K ;

GRIMELIUS, L .

PATHOLOGY RESEARCH AND PRACTICE, 1989, 185 (03) :373-380

[2] PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].

Afshar-Oromieh, A. ;

Malcher, A. ;

Eder, M. ;

Eisenhut, M. ;

Linhart, H. G. ;

Hadaschik, B. A. ;

Holland-Letz, T. ;

Giesel, F. L. ;

Kratochwil, C. ;

Haufe, S. ;

Haberkorn, U. ;

Zechmann, C. M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495

[3] [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH [J].

Afshar-Oromieh, A. ;

Haberkorn, U. ;

Eder, M. ;

Eisenhut, M. ;

Zechmann, C. M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (06) :1085-1086

[4]

JOHNSON D E, 1972, Journal of Surgical Oncology, V4, P207, DOI 10.1002/jso.2930040305

[5] The Role of Neuroendocrine Cells in Prostate Cancer: A Comprehensive Review of Current Literature and Subsequent Rationale to Broaden and Integrate Current Treatment Modalities [J].

Lugnani, F. ;

Simone, G. ;

Biava, P. M. ;

Ablin, R. J. .

CURRENT MEDICINAL CHEMISTRY, 2014, 21 (09) :1082-1092

[6] Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis [J].

Mannweiler, Sebastian ;

Amersdorfer, Peter ;

Trajanoski, Slave ;

Terrett, Jonathan A. ;

King, David ;

Mehes, Gabor .

PATHOLOGY & ONCOLOGY RESEARCH, 2009, 15 (02) :167-172

[7]

Moul Judd W, 2003, Clin Prostate Cancer, V2, P87, DOI 10.3816/CGC.2003.n.015

[8] Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases [J].

Sweat, SD ;

Pacelli, A ;

Murphy, GP ;

Bostwick, DG .

UROLOGY, 1998, 52 (04) :637-640

← 1 →